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Abstract
Background: Mutations in Wilm’s tumor 1 (WT1) gene is one of the commonly reported genetic mutations in
children with steroid resistant nephrotic syndrome (SRNS). We report the results of direct sequencing of exons 8
and 9 of WT1 gene in 100 children with SRNS from a single centre. We standardized and validated High Resolution
Melt (HRM) as a rapid and cost effective screening step to identify individuals with normal sequence and distinguish it
from those with a potential mutation. Since only mutation positive samples identified by HRM will be further
processed for sequencing it will help in reducing the sequencing burden and speed up the screening process.
Methods: One hundred SRNS children were screened for WT1 mutations in Exon 8 and 9 using Sanger sequencing.
HRM assay was standardized and validated by performing analysis for exon 8 and 9 on 3 healthy control and 5
abnormal variants created by site directed mutagenesis and verified by sequencing. To further test the clinical
applicability of the assay, we screened additional 91 samples for HRM testing and performed a blinded assessment.
Results: WT1 mutations were not observed in the cohort of children with SRNS. The results of HRM analysis were
concordant with the sequencing results.
Conclusion: The WT1 gene mutations were not observed in the SRNS cohort indicating it has a low prevalence. We
propose applying this simple, rapid and cost effective assay using HRM technique as the first step for screening the
WT1 gene hot spot region in a clinical setting.
Keywords: Children, WT1, Steroid resistant, High resolution melt, Mutation
Background
Steroid resistant nephrotic syndrome (SRNS) remains
one of the most common intractable causes of end-stage
renal disease (ESRD) in children with 50–70% reaching
ESRD within 5–10 years of diagnosis [1, 2]. Discovery of
pathogenic variants in at least 40 genes responsible for
maintenance of podocyte structure and functions with
sporadic SRNS helped in identifying a distinct subgroup
of SRNS [3, 4]. This group of children are generally un-
responsive to immunosuppressive medications, and the
disease does not recur post-transplantation [5, 6]. Thus,
mutational analysis in SRNS is important because it
helps in preventing unnecessary exposure to immuno-
suppressants and their adverse effects, besides establish-
ing a molecular diagnosis and clear prognosis. WT1
mutations are associated with a spectrum of renal and
extra-renal manifestations. Mutations in WT1 (Wilm’s
tumour 1) are detected in 5–9% of children with SRNS
* Correspondence: anil.vasudevan@sjri.res.in
1Division of Molecular Medicine, St. John’s Research Institute, Bangalore, India
2Department of Pediatric Nephrology, St. John’s Medical College Hospital,
Bangalore 560034, India
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Siji et al. BMC Medical Genetics  (2017) 18:3 
DOI 10.1186/s12881-016-0362-7
with a higher frequency in those with congenital or in-
fantile onset of nephrotic syndrome and in children with
Diffuse Mesangial Sclerosis [7–9]. Most of the WT1 mu-
tations occur mainly in exon 8 and 9, which code for
zinc finger domains 2 and 3, respectively which can lead
to isolated SRNS, two distinct clinical syndromes that
are associated with SRNS (1) Denys-Drash syndrome
(DDS) (2) Frasier syndrome (FS), and conditions without
Nephrotic syndrome such as Wilm’s tumor, Meacham
syndrome and somatic Mesothelioma (Online Mendelian
Inheritance in Man, http://www.ncbi.nlm.nih.gov/omim
database). DDS, mostly caused by mutations in exon 8
or 9 of WT1 is characterized by congenital/infantile NS,
ambiguous genitalia, and a high risk for Wilms tumor
while FS caused by mutations in the donor splice site at
intron 9 is characterized by SRNS due to focal segmental
glomerulosclerosis (FSGS), gonoadoblastoma and 46 XY
disorder in sex development with sex reversal [10–12].
The current approach used for identifying pathogenic
variants in the gene is Sanger’s (Direct) sequencing. It
requires additional steps after amplification of the target
by polymerase chain reaction (PCR) leading to a higher
turnaround time. Sequencing also adds to the cost, a
major constraint in emerging countries in the manage-
ment of this disease. Since incidence of WT1 mutation
in SRNS is lower in Asian population, as compared to
western countries, we expect that majority of the pa-
tients tested in the Indian population will have normal
(wild type) sequence [13–17]. Hence a fast and cost ef-
fective high throughput screening assay to identify indi-
viduals with normal sequence is an unmet clinical need.
The proposed two – step screening method will help in
reducing the sequencing burden by elimination of sam-
ples with normal sequence and proceeding for Sanger’s
sequencing of only those samples suspected of carrying
a mutation. The approach will also aid in quickening the
clinical decision making process.
One novel technique that is increasingly being used as
screening tool for identification of normal or abnormal
sequence pattern in the entire amplicon is the high reso-
lution melting (HRM) analysis [18]. The principle of
HRM is that a single base change in the amplicon influ-
ences the thermodynamic stability of the duplex result-
ing in a slight change in the melting temperature (Tm)
and the fluorescence absorbance behaviour during the
melting of the DNA double strand to single strands.
HRM is a rapid, closed tube high throughput system
wherein PCR amplification and subsequent analysis are
sequentially performed in the same tube and therefore
more convenient and less labor intense compared to
other mutation scanning methods such as denaturing
high performance liquid chromatography (DHPLC) and
fluorescent multiplexed-PCR analysis (FMPA). Being a
closed tube method, the risk of contamination is low. In
addition, the sample identified to have a probable muta-
tion using HRM can be further processed for sequencing
thereby avoiding additional PCR. HRM also has better
sensitivity and specificity than DHPLC [19]. Besides,
HRM is not capital intensive since it can be performed
directly with optimized primers without any other probe
on a PCR instrument that collect fluorescent data with
fine temperature resolution at the end of the PCR.
The aim of our study is to report for the first time the
frequency and spectrum of WT1 mutations in Indian
children with sporadic SRNS from a single center. Since
we observed low prevalence of pathogenic variants in
exons 8 and 9 of WT1, we developed and validated a
simple assay based on high-resolution melting analysis
to quickly identify normal sequence profiles of WT1
exon 8 and 9 in a clinical setting to exclude them from
being further processed for Sanger sequencing.
Methods
Subjects
One hundred children diagnosed with initial SRNS or
congenital nephrotic syndrome (NS) as defined by stand-
ard guidelines were included after informed consent and
clinical data were recorded [20]. Children with second-
ary nephrotic syndrome or those who had mutation in
Podocin (NPHS2) gene were excluded. Blood samples
for mutational analysis were obtained and genomic
DNA was extracted from peripheral blood leukocytes by
the phenol chloroform method [21]. The quantity and
quality of DNA was estimated using Nano-Drop ND-
1000 (Thermo Scientific, India). To differentiate the mu-
tations from polymorphisms, DNA from 50 healthy
young adults, were used as controls.
Mutation analysis by Sanger sequencing
Exons 8 and 9 including the splice site at intron 9 of
WT1 gene of all the recruited subjects were amplified
using oligos (WT1 _E8_F_A and WT1 _E8_R_D for exon
8; WT1 _E9_F_A and WT1 _E9_R_D for exon 9) located
on the intron-exon boundaries (Table 1). Oligos were
designed Primer 3 plus software [22]. Bi-directional se-
quencing of the amplified products was performed using
Big Dye Terminator v3.1 Cycle Sequencing Kit and ana-
lysed on an ABI 3730xl genetic analyser (Applied Biosys-
tems, Foster City, CA) (Eurofins Genomics India Pvt
Ltd, Bangalore, India). Sequences were evaluated for var-
iants using the FinchTV 1.4.0 (Geospiza, Inc.; Seattle,
WA, USA; http://www.geospiza.com) and NCBI BLAST.
Construction of mutated sequence by site directed
mutagenesis
We used the site directed mutagenesis technique to
introduce a mutation in each of the exons 8 and 9 in
order to be able to validate the HRM technique as
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described by Heish et al., 2013 [23]. The following single
nucleotide change from the wild type were introduced:
c.1079G > A;p.C360Y (hg19 - c.1283G > A;p.C428Y) and
c.1119C > A;p.H373Q (hg19 - c.1323C > A; p.H441Q) in
Exon 8 and c.1180C > T;p.R394W (hg19 - c,1384C >
T;p.R462W), c.1190A > C;p.H397P (hg19 - c.1394A > C;
p.H465P) and c.A1200C > T;p.H401Y (hg19 - c.1405C >
T;p.H469Y) in exon 9 [24–27]. Round 1 PCR was car-
ried out using mutagenic oligos (2 oligos per mutation;
Table 1). In the second round of PCR, both the first
round amplicon products were mixed in 1:1 ratio and
re-amplified to produce the full length PCR products of
exon 8 and 9 of the WT1 gene using the same oligos
that were used for Sanger sequencing. The insertion of
point mutations was verified by Sanger sequencing.
High resolution melt analysis for WT1 exon scanning
The oligos sequence that was used for Sanger sequen-
cing was also used for HRM. Standardization of the
assay to determine the optimal annealing temperature
and characterize the melt curve profiles of exons 8 and 9
of WT1 gene was performed on five healthy control
samples that were previously sequenced and confirmed
to have wild type sequence. The standardization runs for
each exon was initially performed separately and subse-
quently, the conditions were standardized to amplify
both the exons in the same run. In brief, each reaction
was performed in a final volume of 10 μl containing
20 ng of DNA, 250nM of each oligo (forward or reverse)
and 1 ×Melt Doctor Master mix (Thermofisher Scientific,
USA). The PCR reaction conditions were as follows: initial
denaturation step at 95 °C for 10 min followed by 45 cycles
of 95 °C for 10s, 56 °C for 15 s, and 72 °C for 15 s. All
HRM runs were performed in duplicate on Step one plus
instrument (Thermofisher Scientific, USA).
For the melt analysis, the PCR products obtained after
amplification were first heated to 95 °C for 1 min and
then rapidly cooled to 40 °C at 1.6 °C per second to
allow heteroduplex formation. The PCR products were
then reheated to 95 °C at 0.01 °C per second. Melt curve
was monitored (by fluorescence emission) from 40 °C to
95 °C. The melt curve analysis was performed by the
resolution melt (HRM) software version 2.0 (Thermo-
fisher Scientific, USA) using default setting. Briefly, the
melt curve data for the amplicons are normalized be-
tween 0 and 100% fluorescent intensity and temperature
shifted (to eliminate temperature difference between
samples) for comparisons. The normalized, temperature-
adjusted plot allows visual comparison of melting curve
shapes to detect heterozygous variants. For the differ-
ence plot, one melting curve is chosen as a reference,
and the difference between each curve and the reference
is plotted against temperature to give a “fluorescence dif-
ference”. The original reference curve becomes a hori-
zontal line at zero. Significant differences in fluorescence
from the horizontal baseline indicate variations in the
dissociation pattern of the amplicons. Differences are
judged as significant if the technical duplicate fall out-
side the range. The derivative plot allowed direct
visualization of the melting temperatures (Tm) and was
used to differentiate between normal sequences of exon
8 and 9. To test for reproducibility, a single analyst
Table 1 Mutagenic oligos (Round 1 PCR) used for site directed mutagenesis in exon 8 and 9 of the WT1 gene
Mutation Oligo Name Oligo sequence 5’–3’ Annealing temperature (°C)
Exon 8



























































Oligos in bold indicate mutagenic oligos
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prepared samples in duplicate and performed the HRM
assay and the same analyst repeated the procedure on a
different day. In addition, the melt curve prediction for
both exons was carried out by the POLAND software
using the nearest neighbor thermodynamic modeling,
and the Blake and Delcourt algorithm [28].
For validation of the assay, five samples with mutations
that were generated by site directed mutagenesis and veri-
fied by sequencing and 3 samples from healthy controls
for each exon were used as positive and negative controls
respectively along with three randomly selected patient
samples. To further test the clinical applicability of the
assay, we included additional 91 previously sequenced
samples from the cohort for HRM testing and a blinded
assessment was performed. The healthy control samples
used in standardization and validation experiment for
exon 8 and 9 were used as reference samples and the
melting profiles of the amplicons were compared with that
of reference samples for each exon.
Results
Clinical profile and WT1 mutations in the cohort
One hundred children with sporadic SRNS (50 females,
50 males) were included in the study (see Table 2 for
clinical profile). Majority of the patients were from the
southern region of India (90%). The median age at the
onset of nephrotic syndrome was 2.5 years (IQR 1.2–
6.2 years). Parental consanguinity was found in 16% of
the families. There were no children with DDS or FS.
Among the patients who underwent renal biopsy, focal
segmental glomerulosclerosis, minimal change disease
and mesangial hyper cellularity was seen in 37, 21 and
12 patients respectively. None of the children biopsied
had diffuse mesangial sclerosis (DMS). Most children
received multiple immunosuppressants with variable
response. Among the children who were recorded to
have received calcineurin inhibitors (Cyclosporine and/
or Tacrolimus), three had complete response, 11 had
partial response and 40 children were calcineurin resist-
ant. Of the 76 children with follow up data, 50 children
maintained normal renal function (three complete re-
mission, 47 had persistent proteinuria), 17 developed
CKD stages II – IV, nine progressed to CKD stage V or
end stage renal disease (6 received renal transplant and
3 died). The median duration for progression to CKD
stage V from onset of disease was 2.7 years. Genomic
DNA of all these samples were screened for mutation in
exon 8 and 9 of WT1 gene by Sanger sequencing. The
samples did not show any mutation or single nucleotide
polymorphism (SNP) in WT1 gene.
Standardization and validation of HRM assay for
identifying normal sequences
The derivative curves, aligned melt curves and the differ-
ence plots of WT1 exon 8 and 9 of 5 healthy control sam-
ples used in the standardization run are presented in
Fig. 1. Exon 8 and 9 produced unique melt curves and
were visually discriminated from each other and they
could be detected in the same PCR run. The melting
temperature (standard deviation) of exon 8 and 9 were
78.8 °C (±0.15) and 80.5 (±0.1) respectively. We observed
high reproducibility of the melting temperature (Tm)
values for a given exon. The melt profiles of WT1 exon 8
and 9 obtained in the standardization run was in concord-
ance with the melt profile obtained using the nearest
neighbor thermodynamic modeling and the Blake and
Delcourt algorithm (POLAND software) (Fig. 2).
The method was validated using the five positive mu-
tated sequences obtained by site directed mutagenesis
methodology along with three healthy controls (wild
type) and three randomly chosen patient samples. All
the samples with mutation had a distinctive melting pat-
tern which was visually discriminated when compared
with those of the wild-type sequences indicating the abil-
ity of the HRM assay to discriminate mutated from wild
type samples (Fig. 3). The HRM profile of patient sam-
ples was similar to that of healthy controls which were
verified by sequencing.
Table 2 Clinical profile of the cohort
Characteristic
Patients (n) 100 (50females/50 males)
Ethnic background (Southern region/
Northern region/Eastern region; %)
90/9/1
Consanguinity (%) 12
Onset of NS (congenital/infantile/childhood
primary SRNS/Unknown; %)
4/4/80/12
Age at diagnosisa (years; Median, IQR) 2.5 (1.2–6.2)
Edema 74%
Proteinuria (yes/unavailable; %) 81/19
Hematuria (Yes/No/unavailable; %) 13/52/35
Hypertension (yes/no/unavailable) 35/45/20
Serum albumin (g/l; Median, Range) 1.7 (1.2–2.3)
Histopathology subtype (%)
Minimal change disease 37







Chronic Kidney disease Stage II-IV 22
End-stage renal disease 12
aincomplete data on 11/100 patients
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To further test the clinical application of this assay, we
screened 91 patient samples that had been previously se-
quenced for Exon 8 and 9 of WT1 gene with the healthy
control samples as reference samples. The analysis of the
HRM data was done independently by two observers in
the following way: the curves were first auto grouped by
the software based on the melt transition. The observers,
who were blinded to the identity of the samples, con-
firmed that the Tm difference obtained between the exon
8 and 9 was same as that obtained in the standardization
assay. The heterozygotes if any were to be identified by
the shapes of their melting curves. There was no change
in the classification by the observers as compared to that
grouped by the software. The Tm of the amplicons, exon
8 and 9 were unambiguously distinguished from each
other in the derivative plot (Fig. 1a). The two exons were
also readily distinguishable in the aligned melting
curve and in the difference plots (amplitude and/or
shape of the curves: Fig. 1b and c). Exons 8 and 9 of
all the patient samples had similar melt profiles as
that of their respective reference sample and reliably
sorted into one of the two distinct groups (Additional
file 1: Figure S1). The melt profile results were identical
to the Sanger’s sequencing results. The HRM results were
obtained in 2 h 15 min, while sequencing required a
minimum of 5 days to obtain the final result. The cost
analysis calculated in the present conditions showed that
conventional PCR followed by Sanger sequencing was
three times costly when compared to high-resolution
melting assay (Additional file 2: Table S1).
Fig. 1 HRM data for exon 8 and 9 of WT1 gene (standardization assay). The melt plots show five wild type control samples, which have been
previously sequenced exons 8 and 9 . For each exon the Derivative plot (dF/dT) (a, b), Normalized melt curve (c, d) and Fluorescence difference
plots (Δ Threshold/Temperature) (e, f) is presented
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Discussion
SRNS is a genetically heterogeneous disorder with a
broad phenotypic spectrum [29, 30]. Our previous study
indicated that the prevalence of Podocin mutation in In-
dian children with SRNS was low as compared to the
Western countries [31]. The present study from a single
centre in India comprising largely of patients from the
southern region of the country (90%) was conducted to
determine whether WT1 mutations could be the cause
of sporadic SRNS in a subset of patients who did not
have Podocin mutation. In our cohort, no subject tested
positive for mutation in WT1. Based on the number of
children tested, the prevalence of WT-1 mutation in In-
dian children with SRNS with 95% confidence is ≤ 3%
[32]. The prevalence of WT1 mutation in children with
SRNS varies according to the population origin and is
summarised in Table 3. Data from large cohort studies
that included children with SRNS from various ethnic
background like central and west European, Turkish,
American, African-American, Hispanic, South Asian,
Arabic, or African, shows that the prevalence of WT1
mutation varies between 1.7 and 9% [9, 26, 33]. Studies
limited to specific ethnic groups also show wide vari-
ation in the prevalence of WT1 mutation with low
prevalence in Japanese and Chinese population and high
prevalence in Greek, Spanish and Korean population
[13–16, 34, 35]. The location and type of WT1 muta-
tions can predict clinical features, histology and renal
outcomes. In the largest cohort study of 61 children with
WT1 mutations, Lipska et al. observed that while mis-
sense mutations were associated with DMS, early onset
SRNS and rapid progression to ESRD, the truncating
mutations were seen in those who had late onset of
SRNS and these children were also at high risk for
Wilm’s tumor [9]. In the same study isolated SRNS was
associated with intronic (KTS) mutations and slow pro-
gression to ESRD. A similar observation was also re-
ported by Chernin et. al., who observed that intronic
mutations (KTS) cause NS with slower progression to
ESRD compared with missense mutation [36]. In an-
other retrospective analysis of 53 mid-European patients,
those with missense mutations required dialysis signifi-
cantly earlier that those with truncating mutations [37].
We could not perform genotype-phenotype correlation
due to absence of mutations in our study. The average
age of onset of nephrotic syndrome in our cohort is very
similar to that reported in other studies suggesting that
age cannot explain the low prevalence WT1 mutation in
our cohort [14–17, 26, 33, 34, 38]. As shown in Table 3
the presence of syndromic SRNS (DDS or FS or patient
with genitourinary tract malformations) can also influ-
ence the frequency WT1 mutation. In the study by
Mucha et al. the prevalence of WT1 mutation decreased
from 6. 3 to 3.9% when patients with genitourinary tract
malformations were excluded [33]. Being a single centre
study with most of the patients from the southern re-
gion, our findings cannot to be generalized to the Indian
population. The present cohort comprised of children
with only isolated SRNS and none of the patients had
DMS on biopsy. The probability of detecting mutations
in WT 1 are higher in children with DDS and FS or in
those with DMS. In addition, we screened only the hot
spot regions of exon 8 and 9 that account for majority of
mutations and not the complete open reading frame of
WT1 gene. These reasons could potentially explain the
absence of WT1 mutation observed.
The heterogenic nature of SRNS makes mutation ana-
lysis costly and time consuming. Since the prevalence of
the WT1 mutation is observed to be low, we standard-
ized a simple and economical assay that will be useful in
Fig. 2 POLAND Melt profile prediction (Blake and Delcourt algorithm) for WT1- Exon 8 and 9. The differentiated hypochromicity at 260 and
280 nm (dA/dT) vs. temperature plot is depicted. Theta is the calculated fraction of base pairs remaining in helical state. Both exon 8 and 9 were
predicted to melt completely at a single temperature and was in concordance with the experimental melt profiles
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the clinic to identify quickly and accurately subjects with
no mutation. We chose HRM assay as a screening tool
because it has been found to be a very useful high
throughput mutation scanning method in various hu-
man diseases [39–41]. The oligo designed for Sanger se-
quencing were also suitable for HRM analysis, and
hence there was no need to design separate set of oligos.
Further, the PCR conditions were optimized in such way
that both exons can be tested in a single run. Performing
simultaneous analysis of the two exons in the same run
saves time as well as cost. The melting curves generated
in this study allowed unambiguous differentiation of
exon 8 and 9 and were highly reproducible. This is the
first report wherein a single HRM run can be used for
screening of both exons 8 and 9 of WT1 gene. Our
HRM results were in complete concordance with con-
ventional Sanger sequencing suggesting that the HRM
gene scanning method can be used to screen for WT1
gene mutation. In contrast to Sanger sequencing, the
use of HRM allows to considerably lower the costs of
gene mutation screening in the clinic by reducing the
number of samples subjected to Sanger sequencing. Use
of this method could reduce costs to 9$ per sample
when compared to Sanger sequencing which is 30$ per
sample, thus proving to be a cost effective method for
gene scanning. We also noted that the turnaround time
is much lower with HRM. The entire analysis, including
the preparation of the reaction mixture, amplification
Fig. 3 HRM Validation assay showing derivative melt plot, normalized melt curve and difference plots for exon 8 and 9 of the WT1 gene. In WT1
exon 8, the wildtype (blue) and the blinded patient sample (maroon) grouped together indicating that they have the same genotype. The mutant
samples c.1079G > A; p.C360Y (orange) and c.1119C > A; p.H373Q (green) were distinguished from the wildtype sample (Fig. 3 a, c and e). Similary
in WT1exon 9, the wildtype (green) and the blinded patient sample (maroon) grouped together and the mutant samples c.1180C > T; p.R394W
(red), c.1190A > C; p.H397P (pink) and c.A1200C > T; p.H401Y (black) were easily distinguished from the wild type (Fig. 3 b, d and f)
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and melting of the products takes a little more than 2 h
and interpretation of the result takes 30 min (Additional
file 2: Table S1). Further, HRM analysis require less
manpower as single technician can perform the test and
screen large number of samples in a single assay. Since
the assay only requires real time PCR equipment, clinical
laboratories can initiate similar screening strategy using
our standardized protocol. The same technique could be
used in screening other genes and risk alleles associated
with SRNS in a similar way. The APOL1 G1 and G2 risk
alleles in the African American population with FSGS is
significantly enriched as compared to the general popu-
lation. HRM will be an ideal technique to rapidly screen
for these alleles in our population [42].
In summary, no pathogenic variant in exon 8 and 9
of WT1 gene was found in the present cohort. We de-
veloped a simple, high throughput approach for identi-
fication of normal variants in WT1 gene which is six
times faster and three times less cost compared with
traditional direct sequencing. The results obtained by
HRM on the clinical samples further support the feasi-
bility of applying the assay as a screening technique in
a clinical setting.
Additional files
Additional file 1: Figure S1. HRM analysis of cohort for exon 8 and 9
of WT1 gene. The melt plots show wild type control samples and
representative patient samples, which have been previously sequenced
exons 8 and 9 . For each exon the Derivative plot (dF/dT) (A,B),
Normalized melt curve (C, D) and Fluorescence difference plots
(Δ Threshold/Temperature) (E, F) is presented. (TIF 3577 kb)
Additional file 2: Table S1. Summary of the properties of High
Resolution Melt and Direct sequencing. (DOCX 12 kb)
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